Acadia Pharmaceuticals (ACAD) FY2017 results: revenue $125 million, up 620.7% on the year
Acadia Pharmaceuticals Inc. (ACAD) reported revenue of $125 million for fiscal 2017, the year ended 31 December 2017, up 620.7% on the year before. Net income was -$289 million, and diluted earnings per share $-2.36. The figures are the company's own, from the 10-K it filed with the SEC on 27 February 2018.
Revenue
$125 million
+620.7% on the year
FY2010FY2017
Operating margin
-234.1%
-1574.1% a year earlier
FY2010FY2017
Net income
-$289 million
FY2010FY2017
Diluted EPS
-$2.36
FY2010FY2017
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Revenue
125
17.3
0.1
+620.7%
Cost of revenue
9.1
3.1
n/a
+195.2%
Gross profit
116
14.3
n/a
+712.7%
Gross margin
92.7%
82.2%
n/a
Research and development
149
99.3
73.9
+50.3%
Selling, general and administrative
255
186
88.3
+36.8%
Operating income
-292
-273
-165
Operating margin
-234.1%
-1574.1%
-269855.7%
Pre-tax income
-288
-270
-164
Income tax
1.1
1.3
0.3
-16.6%
Net income
-289
-271
-164
Net margin
-231.7%
-1565.9%
-269578.7%
Diluted EPS
-$2.36
-$2.34
-$1.63
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Operating cash flow
-218
-208
-122
Capital expenditure
0.8
1.5
2.1
-46.1%
Free cash flow
-219
-210
-124
Free cash flow margin
-175.0%
-1211.2%
-203173.8%
Cash from investing
92.5
-262
n/a
Cash from financing
31.2
534
n/a
-94.2%
Depreciation and amortisation
2.7
1.8
0.6
+48.4%
Share-based compensation
75.5
55.3
40.2
+36.7%
Shares outstanding at period end
124m
121m
102m
+2.5%
Balance sheet
$ million
FY2017
FY2016
FY2015
On the year
Last 8 years
Shareholders' equity
335
518
200
-35.3%
Other liabilities
49.2
42.7
22.1
+15.2%
Total liabilities and equity
385
561
222
-31.5%
Fixed assets
2.7
3.1
2.2
-13.6%
Intangible assets
5.5
7.0
n/a
-21.1%
Investments
272
365
113
-25.6%
Cash and equivalents
69.4
164
102
-57.6%
Receivables
17.3
5.9
n/a
+193.8%
Inventory
5.2
4.2
n/a
+25.7%
Other assets
12.4
11.9
4.6
+3.6%
Total assets
385
561
222
-31.5%
10-K for the year ended 31 December 2017, filed 27 February 2018: the filing.